Literature DB >> 15256032

An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states.

Christina Scheel Zinn1, Henrik Westh, Vibeke Thamdrup Rosdahl.   

Abstract

During 1996, 4065 consecutive Staphylococcus aureus strains from different patients were collected in 21 worldwide hospital laboratories. The strains, their resistance pattern, and hospital demographic data were forwarded to Statens Serum Institut where the strains were typed and data analyzed. Resistance patterns varied by region and resistance to other antibiotics than methicillin were mainly related to the occurrence of methicillin resistance, except for mupirocin, rifampicin, and fusidic acid. Methicillin-resistant S. aureus (MRSA) occurred with low levels in hospitals in Northern Europe (<1%), increasing levels in middle-European countries, United States, New Zealand, and Australia (6-22%), and very high levels in Southern European countries as well as in parts of the United States, Asia, and South Africa (28-63%). MRSA found in large hospitals were more resistant to other antibiotics than MRSA found in smaller hospitals serviced by the same laboratory. No difference in resistance levels was seen for methicillin-susceptible S. aureus (MSSA) isolated in large or small hospitals. Intensive Care Units had the highest level of MRSA. Strains from the lower respiratory tract showed the highest resistance levels and blood isolates the lowest. A dominating MRSA clone was found in hospitals with an MRSA frequency of more than 10%. Pulsed-field gel electrophoresis (PFGE) typing recognized several of these clones as international epidemic MRSA (E-MRSA). All MSSA isolates were phage typed (typeability 85.4%) and divided in seven major phage patterns. Isolates of all patterns were found in all hospitals except one, indicating that the MSSA seldom represented the spread of clones within the hospital. The comparison should evaluate the prevalence of community-acquired MRSA and identify internationally E-MRSA. The present study gives a snapshot of the MRSA situation, but it is important to build up a continuous national and international surveillance, because MRSA is a global socioeconomic problem. Global infection control procedures, including rational antibiotic use, should be agreed on. The accompanying paper will address the issue of antibiotic consumption and MRSA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256032     DOI: 10.1089/1076629041310055

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  28 in total

1.  Molecular characterization of clinical methicillin-resistant Staphylococcus aureus isolates in South Africa.

Authors:  A Moodley; W F Oosthuysen; A G Dusé; E Marais
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

2.  Phenotypic and genetic characterisation of methicillin-resistant Staphylococcus aureus strains isolated from the university hospitals of Debrecen.

Authors:  J Szabó; Z Dombrádi; O Dobay; P Orosi; J Kónya; K Nagy; F Rozgonyi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-02       Impact factor: 3.267

3.  Epidemiology of Staphylococcus aureus harboring the mecA or Panton-Valentine leukocidin genes in hospitals in Java and Bali, Indonesia.

Authors:  Dewi Santosaningsih; Sanarto Santoso; Nyoman S Budayanti; Kuntaman Kuntaman; Endang S Lestari; Helmia Farida; Rebriarina Hapsari; Purnomo Hadi; Winarto Winarto; Catarina Milheiriço; Kees Maquelin; Diana Willemse-Erix; Alex van Belkum; Juliëtte A Severin; Henri A Verbrugh
Journal:  Am J Trop Med Hyg       Date:  2014-02-24       Impact factor: 2.345

4.  Cooccurrence of predominant Panton-Valentine leukocidin-positive sequence type (ST) 152 and multidrug-resistant ST 241 Staphylococcus aureus clones in Nigerian hospitals.

Authors:  Kenneth O Okon; Patrick Basset; Auwalu Uba; Johnson Lin; Bukola Oyawoye; Adebayo O Shittu; Dominique S Blanc
Journal:  J Clin Microbiol       Date:  2009-07-15       Impact factor: 5.948

5.  Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in dogs and cats: a case-control study.

Authors:  Ricardo Jorge Soares Magalhães; Anette Loeffler; Jodi Lindsay; Mick Rich; Larry Roberts; Heather Smith; David Hugh Lloyd; Dirk Udo Pfeiffer
Journal:  Vet Res       Date:  2010-04-29       Impact factor: 3.683

Review 6.  Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature.

Authors:  Andrew F Shorr
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 7.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus.

Authors:  Benjamin P Howden; Timothy P Stinear; David L Allen; Paul D R Johnson; Peter B Ward; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

9.  Fusidic Acid Resistance Determinants in Methicillin-Resistant Staphylococcus aureus Isolated in Kuwait Hospitals.

Authors:  Halimah A Boloki; Wasmiyah F Al-Musaileem; Wadha AlFouzan; Tina Verghese; Edet E Udo
Journal:  Med Princ Pract       Date:  2021-07-13       Impact factor: 1.927

10.  Livestock origin for a human pandemic clone of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Laura E Spoor; Paul R McAdam; Lucy A Weinert; Andrew Rambaut; Henrik Hasman; Frank M Aarestrup; Angela M Kearns; Anders R Larsen; Robert L Skov; J Ross Fitzgerald
Journal:  mBio       Date:  2013-08-13       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.